Genomic Tumor Board (GTB) Sessions

“The information presented at the tumor boards is timely, relevant and difficult for the community oncologist to acquire in other ways.”
- Sarah Ketchum, M.D., MCGI Clinician

 

 

What is the best way to integrate somatic cancer panel testing into my clinical practice? When is the best time to incorporate genomic testing during the course of my patient's care? Will repeated testing track cancer evolution and refine treatment regimens?

Addressing these questions ultimately depends on the clinician’s ability to understand the genomic information provided by tests and to efficiently extract and evaluate actionable results.

The Maine Cancer Genomics Initiative (MCGI) aims to overcome these barriers. Join us for an upcoming GTB session!

During a genomic tumor board meeting, genomic tumor testing results are discussed with a panel of expert external advisors, oncologists, pathologists from the MCGI network, and clinical trial and genomics experts. The goal of the sessions is to provide interpretation support for treating clinicians and to engage the assembled community of MDs in discussion of potential treatment options for the patient.

How to Join a GTB Session

The MCGI Genomic Tumor Board meetings convene by video-teleconference (VTC), allowing providers from across the State of Maine to access this educational activity without need for travel. VTC access information is provided in an invite to MCGI-study enrolled clinicians. GTB meetings are 30 minutes to 1 hour in length. 

Due to the virtual format of the sessions, physician sign-in for CME credit is recorded as a screen-shot image of the participants list within the VTC software, or on a hand copy sign-in sheet for in-person attendees at MCGI study sites.
    
CME evaluations are sent electronically at the end of the year-long GTB session series to signed-in attendees. Upon completing and submitting the evaluation, attendees are awarded up to the maximum CME credits for which they are eligible.

Clinicians interested in attending may contact us at mcgi@jax.org to be added to the invitation list.

2022 Session Dates

All sessions convene via video-teleconference (VTC) in U.S. Eastern Time.  

JANUARY

  • Wednesday, January 5, at 8:00 a.m., with SMHC
  • Wednesday, January 12, at 12:30 p.m., with Pen Bay Medical Center
  • Tuesday, January 18, at 12:15 p.m., with HACCC
  • Thursday, January 20, at 9:00 a.m., with York Hospital
  • Thursday, January 20, at 4:00 p.m., with Northern Light
  • Wednesday, January 26, at 12:00 p.m., with MMP Oncology
  • Monday, January 31, at 12:00 p.m., with A.R. Gould Hospital

FEBRUARY

Tuesday, February 1, at 9:00 a.m., with Neuro-Oncology
Friday, February 4, at 7:00 a.m., with CMMC
Wednesday, February 9, at 12:30 p.m., with Pen Bay Medical Center
Thursday, February 10, at 11:00 a.m., with Pediatric Oncology
Tuesday, February 15, at 12:15 p.m., with HACCC
Thursday, February 17, at 4:00 p.m., with Northern Light
• Wednesday, February 23, at 12:00 p.m., with MMP Oncology
 Thursday, February 24, at 12:00 p.m., with Mercy Hospital
 Monday, February 28, at 4:30 p.m., with Cary Medical Center


MARCH

Wednesday, March 2, at 8:00 a.m., with SMHC
Wednesday, March9, at 12:30 p.m., with Pen Bay Medical Center
Tuesday, March 15, at 12:15 p.m., with HACCC
Thursday, March 17, at 9:00 a..m., with York Hospital
Wednesday, March 23, at 12:00 p.m., with MMP Oncology
 Wednesday, March 30, at 12:00 p.m., with MDI Hospital/MCMH


APRIL

Friday, April 1, at 7:00 a.m., with CMMC
Tuesday, April 5, at 9:00 a.m., with Neuro-Oncology
Wednesday, April 13, at 12:30 p.m., with Pen Bay Medical Center
Thursday, April 14, at 11:00 a.m. with Pediatric Oncology
• Tuesday, April 19, ay 12:15 p.m., with HACCC
• Thursday, April 21 at 12:00 p.m., with Mercy Hospital
• Thursday, April 21, at 4:00 p.m., with Northern Light
• Monday, April 25, at 4:30 p.m., with Cary Medical Center
• Wednesday, April 27, at 12:00 p.m., with MMP Oncology
• Friday, April 29, at 9:00 a.m., with Gynecology-Oncology

MAY

Wednesday, May 4, at 8:00 a.m., with SMHC
Wednesday, May 11, at 12:30 p.m., with Pen Bay Medical Center
Tuesday, May 17, at 12:15 p.m., with HACCC
Thursday, May 19, at 9:00 a.m., with York Hospital
Thursday, May 19, at 4:00 p.m. with Northern Light
Monday, May 23, at 12:00 p.m., with A.R. Gould Hospital
Wednesday, May 25, at 12:00 p.m., with MMP Oncology

JUNE

 • Friday, June 3, at 7:00 a.m., with CMMC
Tuesday, June 7, at 9:00 a.m., with Neuro-Oncology
Wednesday, June 8, at 12:30 p.m., with Pen Bay Medical Center
Thursday, June 9, at 11:00 a.m., with Pediatric Oncology
Thursday, June 16, at 4:00 p.m., with Northern Light
Tuesday, June 21, at 12:15 p.m., with HACCC
Wednesday, June 22, at 12:00 p.m., with MMP Oncology
Monday, June 27, at 4:30 p.m., with Cary Medical Center
Wednesday, June 29, at 12:00 p.m., with MDI Hospital/MCMH
Thursday, June 30, at 12:00 p.m., with Mercy Hospital


JULY


Wednesday, July 6, at 8:00 a.m., with SMHC
Wednesday, July 13, at 12:30 p.m., with Pen Bay Medical Center
Tuesday, July 19, at 12:15 p.m., with HACCC
Thursday, July 21, at 9:00 a.m., with York Hospital
Thursday, July 21, at 4:00 p.m., with Northern Light
Wednesday, July 27, at 12:00 p.m., with MMP Oncology
Friday, July 29, at 9:00 a.m., with Gynecology Oncology

AUGUST

Tuesday, August 2, at 9:00 a.m., with Neuro-Oncology
Friday, August 5, at 7:00 a.m., with CMMC
Wednesday, August 10, at 12:30 p.m., with Pen Bay Medical Center
Thursday, August 11, at 11:00 a.m., with Pediatric Oncology
Tuesday, August 16, at 12:15 p.m., with HACCC
Thursday, August 18, at 4:00 p.m., with Northern Light
Monday, August 22, at 4:30 p.m., with Cary Medical Center
Wednesday, August 24, at 12:00 p.m., with MMP Oncology
Thursday, August 25, at 12:00 p.m., with Mercy Hospital
Monday, August 29, at 12:00 p.m., with A.R. Gould Hospital
Wednesday, August 31, at 12:00 p.m., with MDI Hospital/MCMH

SEPTEMBER

Wednesday, September 7, at 8:00 a.m., with SMHC
Wednesday, September 14, at 12:30 p.m., with Pen Bay Medical Center
Thursday, September 15, at 9:00 a.m., with York Hospital
Thursday, September 15, at 4:00 p.m., with Northern Light
Tuesday, September 20, at 12:15 p.m., with HACCC
Wednesday, September 28, at 12:00 p.m., with MMP Oncology
Friday, September 30, at 9:00 a.m., with Gynecology Oncology

OCTOBER

Tuesday, October 4, at 9:00 a.m., with Neuro-Oncology
Friday, October 7, at 7:00 a.m., with CMMC
Wednesday, October 12, at 12:30 p.m., with Pen Bay Medical Center
Thursday, October 13, at 11:00 a.m., with Pediatric Oncology
Tuesday, October 18, at 12:15 p.m., with HACCC
Thursday, October 20, at 12:00 p.m., with Mercy Hospital
Thursday, October 20, at 4:00 p.m., with Northern Light
Monday, October 24, at 4:30 p.m., with Cary Medical Center
Wednesday, October 26, at 12:00 p.m., with MMP Oncology
Monday, October 31, at 12:00 p.m., with A.R. Gould Hospital


NOVEMBER

Wednesday, November 2, at 8:00 a.m., with SMHC
Wednesday, November 9, at 12:30 p.m., with Pen Bay Medical Center
Tuesday, November 15, at 12:15 p.m., with HACCC
Thursday, November 17, at 9:00 a.m., with York Hospital
Thursday, November 17, at 4:00 p.m., with Northern Light
Wednesday, November 30, at 12:00 p.m., with MDI Hospital/MCMH


DECEMBER

Friday, December 2, at 7:00 a.m., with CMMC
Tuesday, December 6, at 9:00 a.m., with Neuro-Oncology
Wednesday, December 7, at 12:00 p.m., with MMP Oncology
Thursday, December 8, at 11:00 a.m., with Pediatric Oncology
Wednesday, December 14, at 12:30 p.m., with Pen Bay Medical Center
Thursday, December 15, at 12:00 p.m., with Mercy Hospital
Thursday, December 15, at 4:00 p.m., with Northern Light
Monday, December 19, at 4:30 p.m., with Cary Medical Center
Tuesday, December 20, at 12:15 p.m., with HACCC

CME Certification

The MCGI GTB sessions feature the presentation of one or more case vignettes, drawn from actual, in-treatment patients who have consented to participate in the MCGI study. Review of all clinical information is done in a coded-manner. Protected health information (PHI) is not disclosed in the GTB meetings.  

Information reviewed includes the patient’s diagnosis, pertinent history of illness, previous treatment approaches, and results from MCGI study-related genomic cancer testing. At the discretion of the presenter, pathology findings and other information about the case pertinent to clinical decision making may also be discussed.  

Commentary and discussion centers on genomic variant interpretation, pathology, oncology, and community knowledge of similar cases. A summary of the discussion of each case is recorded as part of the session's official minutes.

After attendance, participants should be able to:

  • Recognize how gene variants are determined, catalogued, curated, and made meaningful to clinicians;
  • Recognize the application of precision medicine in clinical care;
  • Assess the use of precision medicine in practice by appraising the benefits and limitations of precision medicine for an individual patient case; and
  • Formulate potential treatment approaches based on interpretation of information presented about the case in the genomic tumor board format.

 

Certified CME Activity 

Target Audience:

Maine clinicians practicing oncology, involved in cancer patient care and/or cancer research, who have enrolled in the MCGI study.

Accreditation and Joint Sponsorship:

The 2022 MCGI GTB sessions are a certified Continuing Medical Education (CME) activity sponsored by the Maine Medical Education Trust (MMET). 

American Medical Association (AMA) Designation Statement: The Maine Medical Education Trust designates this live activity for a maximum of 70 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Committee on Continuing Medical Education and Accreditation (CCMEA) Accreditation Statement: Maine Medical Education Trust is accredited by the Maine Medical Association's Committee on Continuing Medical Education and Accreditation to provide continuing medical education (CME) to practicing physicians.

Joint Sponsorship: This activity has been planned and implemented in accordance with the Essentials and Standards of the Maine Medical Association's Committee on Continuing Medical Education and Accreditation through the partnership of Maine Medical Education Trust and The Jackson Laboratory.

The Maine Medical Education Trust is accredited by the Maine Medical Association to provide CME activities for physicians.

 

Certified American Board of Pediatrics (ABP) Maintenance of Certification (MOC) Activity 

MOC Credit:

In addition to CME credits, Maintenance of Certification (MOC) for the American Board of Pediatrics (ABP) Part 2 credits is offered for select Pediatric Genomic Tumor Boards. 

Target Audience:

Maine clinicians practicing pediatric oncology, involved in cancer patient care and/or cancer research who have enrolled in the MCGI study.

Accreditation and Joint Sponsorship:

The 2022 MCGI Pediatric GTB sessions are a certified ABP MOC Activity Sponsored by the Maine Medical Education Trust. 

MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 5 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to AACME for the purpose of granting ABP MOC credit.

CCMEA Accreditation Statement: Maine Medical Education Trust is accredited by the Maine Medical Association's Committee on Continuing Medical Education and Accreditation to provide continuing medical education (CME) to practicing physicians.

Joint Sponsorship: This activity has been planned and implemented in accordance with the Essentials and Standards of the Maine Medical Association's Committee on Continuing Medical Education and Accreditation through the partnership of Maine Medical Education Trust and The Jackson Laboratory.

The Maine Medical Education Trust is accredited by the Maine Medical Association to provide CME activities for physicians.

 

Claiming MOC and CME Credit

Claiming ABP MOC Credit:
At the end of the 2022 GTB series, an electronic evaluation will be sent to participants who logged into the VTC, signed an in-person hard copy attendance sheet, and/or made themselves known on the audio teleconference line, as recorded in the session minutes. 

ABP MOC credit is MOC Part 2 Credit(s) TM and is intended for physicians and will be uploaded to the ABP records via the PARS network for any eligible clinician who completes the requirements and the authorization form.

Participants may claim credit for each pediatric session they attend. A series certificate is provided after the end of the calendar year totaling all credits received for a participant for the 2022 series. 
 
Claiming CME Credit:
At the end of the 2022 GTB series an electronic evaluation will be sent to participants who logged into the VTC, signed an in-person hard copy attendance sheet and/or made themselves known on the audio teleconference line. 

CME credit is AMA PRA Category 1 Credit(s) TM and is intended for physicians; however, the MCGI GTB session series will offers CME credit documentation to any participant claiming it who has completes the session evaluation at the series' conclusion at the end of the calendar year. For non-clinician participants, it is their responsibility to determine if their respective licensure agency accepts these credits. 

Participants may claim credit for each session they attend. A series certificate is provided after the end of the calendar year totaling all credits received for a participant for the 2022 series. 

 

Disclosures 

There is no commercial support for the Maine Cancer Genomics Initiative (MCGI) or its educational activities. MCGI is a program of The Jackson Laboratory funded through a generous grant from the Harold Alfond® Foundation.
 
The Jackson Laboratory (www.jax.org) is an independent, 501(c)3 nonprofit biomedical research institution with nearly 3,000 employees. Headquartered in Bar Harbor, Maine, it has a National Cancer Institute-designated Cancer Center, a facility in Sacramento, Calif., and a genomic medicine institute in Farmington, Conn. Its mission is to discover precise genomic solutions for disease and empower the global biomedical community in the shared quest to improve human health.
 
Founded in 1950, Harold Alfond® Foundation furthers the philanthropic legacy of Harold Alfond, the founder of Dexter Shoe Company and a longtime supporter of Maine communities in which he and his family worked and resided. Harold Alfond awarded matching challenge grants to organizations to build community partnerships and to inspire and leverage additional giving by others. He ensured his philanthropy would live on by committing nearly all of his wealth to the Foundation, which continues to support charitable causes in the State of Maine.
 
Americans with Disabilities Act (ADA):
 
Services for the Disabled. If special arrangements are required for an individual with a disability to attend this course please contact Jennifer Bourne at The Jackson Laboratory, at 207-288-6113 or jennifer.bourne@jax.org.